PAASP

Executive Summary

PAASP is a Germany-based consulting and auditing firm established in 2015 that addresses critical operational risks in biopharmaceutical R&D by assessing research data quality. The company offers services, training, and its proprietary PAASPort® platform to help clients identify sources of bias, improve data-driven decision-making, and enhance R&D productivity. Serving a global clientele of academic scientists, biotech innovators, funders, and investors, PAASP positions itself as a key enabler of more reliable and reproducible research. Its focus on data integrity aligns with growing industry and regulatory emphasis on reducing wasteful spending and increasing the probability of success in drug development. As a private company in the pre-clinical stage, PAASP's scalable platform model and consulting expertise could drive future growth, though its impact remains tied to adoption rates and market awareness of research quality issues.

Upcoming Catalysts (preview)

• Q4 2026Launch of Enhanced PAASPort® Platform with AI Integration70% success
• H2 2026Strategic Partnership with Major Pharma or CRO50% success
• Q2 2027Regulatory Guidance on R&D Data Quality Standards80% success